# US 8,278,286 B2 · Use of gp130 activators in diabetic neuropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,286 B2
- Document ID: US8278286B2
- Status: Granted
- Kind: B2
- Application number: 12/754,335
- Filed: 2010-04-05
- Published: 2010-07-29
- Granted: 2012-10-02
- Earliest claimed: 2001-10-11
- Assignees: Merck Serono SA
- Inventors: Michel Dreano; Pierre-Alain Vitte
- Web page: https://patentgrep.com/patent/US8278286B2

## CPC

- A61K 38/204: {IL-6}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2750/10011: Circoviridae
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.

## Claims

### Claim 1

A method for treating diabetic neuropathy, comprising causing an effective amount of a substance signaling through gp130 to enter the system of a patient in need thereof, wherein said substance
a) comprises interleukin-6 (IL-6);
b) is a fragment of a) which binds to gp80 and initiates signaling through gp130;
c) is a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130; or
d) is a salt, fused protein or functional derivative of a), b), or c) which initiates signaling through gp130.

### Claim 2 (depends on 1)

A method according to claim 1, wherein said fused protein is an immunoglobulin (Ig) fusion.

### Claim 3 (depends on 1)

A method in accordance with claim 1, wherein said causing step comprises administering to said patient a vector for inducing and/or enhancing the endogenous production of IL-6 in a cell.

### Claim 4 (depends on 1)

A method in accordance with claim 1, wherein said causing step comprises administering a cell that has been genetically modified to produce said substance.

### Claim 5 (depends on 1)

A method according to claim 1, wherein said fused protein is an IL-6 receptor fusion.

### Claim 6 (depends on 1)

The method of claim 1, wherein said substance is
a) an IL-6R/IL-6 chimera;
b) a fragment of a) which binds to and initiates signaling through gp130;
c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130;
d) salt, fused protein or functional derivative of a), b), c) which initiates signaling through gp130.

### Claim 7 (depends on 1)

The method of claim 1, wherein said substance is a substance according to (a) or (b), or a salt thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein said substance is a substance according to (a), or a salt thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein said substance is IL-6, or a salt thereof.

### Claim 10 (depends on 1)

The method of claim 1, said vector comprising a coding sequence encoding said substance, and a promoter, functional in said cell, operably linked to said coding sequence, whereby said coding sequence is expressed and said substance is produced by said cell.

### Claim 11 (depends on 3)

The method of claim 3 wherein the vector is a viral vector.

### Claim 12 (depends on 3)

The method of claim 3 wherein the vector is a lentiviral vector.

### Claim 13 (depends on 10)

The method of claim 10 wherein the promoter is the cytomegalovirus (CMV) promoter.

### Claim 14

A method for treating diabetic neuropathy, comprising causing an effective amount of a substance signaling through gp130 to enter the system of a patient in need thereof, wherein said substance is:
a) interleukin-6 (IL-6);
b) a fragment of a) which binds to gp80 and initiates signaling through gp130;
c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130,
or a variant of a N-terminal truncation fragment of a) which binds to gp80 and initiates signaling through gp130, said fragment differing from a) solely by deletion of one or more consecutive amino acid residues from the N-terminal of a), said variant having at least 90% sequence identity with said N-terminal truncation fragment and said variant initiating signaling through gp130;
d) a fused protein comprising a), b), or c), that initiates signaling through gp130,
e) a salt or functional derivative of a), b), c) or d), which initiates signaling through gp130.

### Claim 15

A method for treating diabetic neuropathy, comprising causing an effective amount of a substance signaling through gp130 to enter the system of a patient in need thereof, wherein said substance is:
a) interleukin-6 (IL-6);
b) a fragment of a) which binds to gp80 and initiates signaling through gp130;
c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130,
d) a fused protein comprising a), b) or c), that initiates signaling through gp130, or
e) a salt or functional derivative of a), b), c), or d), which initiates signaling through gp130.
